Galera appoints eugene p. kennedy, m.d.

Malvern, pa., sept. 01, 2022 (globe newswire) -- galera therapeutics, inc. (nasdaq: grtx), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the appointment of eugene p. kennedy, m.d., f.a.c.s., as chief medical officer (cmo). dr. kennedy is a renowned johns hopkins-trained surgical oncologist and former chief of pancreatic and hepatobiliary surgery at thomas jefferson university with over 15 years' experience in clinical development and biopharma leadership. he will succeed jon t. holmlund, m.d., who will retire at the end of this year. in the interim, dr. kennedy and dr. holmlund will work together closely to ensure a smooth and successful transition, with particular focus on the preparation for the company's submission of an nda to the u.s. fda for avasopasem by the end of 2022.
GRTX Ratings Summary
GRTX Quant Ranking